Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations
Haemonetics (NYSE:HAE) reported Q2 CY2026 results. Revenue rose 5.6% year on year to $339.4 million, exceeding Wall Street estimates by 2.8%. Non-GAAP adjusted EPS was $1.14, up from $1.10 and 5.8% above consensus. Analysts expect revenue growth of about 5% over the next 12 months and full-year EPS to rise from $5.01 to $5.36.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat revenue and adjusted EPS expectations, but adjusted operating margin contracted YoY, and the article notes the stock traded down 3.1% immediately after the results.
Market read
Traders can reassess near-term estimate risk for HAE after the reported beat, while monitoring margin trajectory given the YoY contraction.
What to watch
Organic revenue growth averaged only 3.2% YoY over two years, and Q2 adjusted operating margin declined 4.5 percentage points YoY, which may outweigh the headline beat.
Background
Haemonetics is a blood products company providing devices and software for blood collection, processing, and management.
Ticker impact
Haemonetics reported Q2 CY2026 sales of $339.4M, up 5.6% YoY, beating Wall Street revenue expectations by 2.8%.
Near-term bias modestly positive, but follow-through depends on whether margin pressure reverses.
Revenue and adjusted EPS both beat consensus, yet adjusted operating margin fell YoY in Q2, which can cap the magnitude of the reaction.
Market effects
Provides a read-through on demand and profitability trends in blood products/healthcare devices, with organic growth averaging 3.2% YoY over two years.
Primarily US-listed healthcare sentiment; no explicit regional spillover beyond NYSE trading.
No direct global macro or international regulatory developments cited.
Counterpoint
The stock drop despite the beat suggests investors may be discounting margin contraction or looking for stronger forward momentum than the article’s cited outlook.
Key entities
- companyHaemonetics
NYSE-listed blood products company reporting Q2 CY2026 sales and adjusted EPS results.
- market_referenceWall Street consensus
Analysts’ revenue and EPS expectations referenced as the benchmark for the beat.